Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
3
×
boston top stories
europe blog main
3
×
europe top stories
life sciences
national blog main
national top stories
clinical trials
fda
abbvie
alkermes
allergan
arena pharmaceuticals
biopharma
boston
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
deals
detroit blog main
detroit top stories
duchenne
eisai
eli lilly
europe
felipe jain
indiana blog main
indiana top stories
jess fiedorowicz
jessica jeffrey
karim calis
licensing
lorcaserin
lumateperone
lung cancer
What
fda
medicine
3
×
drug
weight
won
alkermes
antipsychotic
approval
benefits
betting
billion
biopharma
cancer
caveats
commonly
deal
designed
duchenne
effect
eisai
favor
flags
gain
gene
higher
historic
incidence
lorcaserin
loss
market
marketing
offer
panel
patients
post
prescribed
psyche
pulls
puts
recently
Language
unset
3
×
Current search:
unset
×
" boston blog main "
×
" europe blog main "
×
medicine
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal